Risks and Benefits of Gene Therapy for Immunodeficiency: a Reality Check

Cavazzano-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease Science 2000 288: 669–672

Hacein-Bey-Abina S et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy N Engl J Med 2002 346: 1185–1193

Lander ES et al. Initial sequencing and analysis of the human genome Nature 2001 409: 860–921

Elleder D, Pavlicek A, Paces J, Hejnar J . Preferential integration of human immunodeficiency virus type 1 into genes, cytogenetic R bands and GC-rich DNA regions: insight from the human genome sequence FEBS Lett 2002 517: 285–286

Schroder AR et al. HIV-1 integration in the human genome favors active genes and local hotspots Cell 2002 110: 521–529

Scherdin U, Rhodes K, Breindl M . Transcriptionally active genome regions are preferred targets for retrovirus integration J Virol 1990 64: 907–912

Weidhaas JB, Angelichio EL, Fenner S, Coffin JM . Relationship between retroviral DNA integration and gene expression J Virol 2000 74: 8382–8389

Ortiz-Urda S et al. Stable nonviral genetic correction of inherited human skin disease Nat Med 2002 8: 1166–1170

Sclimenti CR, Thyagarajan B, Calos MP . Directed evolution of a recombinase for improved genomic integration at a native human sequence Nucleic Acids Res 2001 29: 5044–5051